Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
geepenil vet. stungulyfsstofn og leysir, lausn 24 g
orion corporation - benzylpenicillinum natríum - stungulyfsstofn og leysir, lausn - 24 g
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
carepen vet spenalyf, dreifa 600 mg
vetcare ltd.* - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
carepen vet (caremast vet) spenalyf, dreifa 600 mg
vetcare oy - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
penovet vet. stungulyf, dreifa 300 .000 a.e./ml
boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
streptocillin vet. stungulyf, dreifa
boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
depomycine, vet. stungulyf, dreifa
intervet international b.v.* - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
procapen vet spenalyf, dreifa 3 g
animedica gmbh* - benzylpenicillinprocainum - spenalyf, dreifa - 3 g
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
penethaone vet (penethamate) stungulyfsstofn og leysir, dreifa 236,3 mg/ml
divasa-farmavic s.a. - penethamate hydriodide - stungulyfsstofn og leysir, dreifa - 236,3 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
benestermycin vet. spenalyf, smyrsli
boehringer ingelheim vetmedica gmbh* - framycetinum súlfat; benethaminum penicillinum inn; penethamate hydroiodide ban - spenalyf, smyrsli
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
aubagio
sanofi winthrop industrie - teriflunomide - margvísleg sclerosis - valdar ónæmisbælandi lyf - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).